

A quality improvement initiative to improve the care of women diagnosed with gestational diabetes

Suneeta Kochhar

Gestational diabetes (GDM) increases the risk of developing type 2 diabetes in later life. Cardiovascular disease (CVD), hypertension and obesity are associated with type 2 diabetes. This means there are missed opportunities for the early detection of modifiable cardiovascular risk factors if GDM is not monitored and, importantly, not managed using a holistic approach. The aim of the present quality improvement initiative was to increase monitoring of glycaemia and cardiovascular risk in women with a history of GDM. A pathway was created to facilitate this and allow assessment and management of modifiable CVD risk factors. The pathway promoted patient choice and encouraged self-management, aligned with the principles of shared decision-making and supported self-management. The pathway had high attendance rates and led to complete recording of HbA_{1c}, BMI and blood pressure, as well as high referral rates to the NHS Diabetes Prevention Programme.

Cardiovascular disease (CVD) encompasses conditions affecting the heart and circulatory system. Modifiable CVD risk factors include smoking, physical inactivity and unhealthy diet. It is recognised that women are underdiagnosed and undertreated for CVD (Jeemon et al, 2026; World Heart Federation, 2026).

Type 2 diabetes is associated with an increased risk of cardiovascular risk factors, such as raised blood pressure (BP) and dyslipidaemia, as well as cardiovascular outcomes such as coronary heart disease and stroke. The excess risk is higher in women with diabetes than in men (Peters et al, 2015).

Gestational diabetes (GDM) increases the risk of having a baby who is large for gestational age, with a consequent increase in the risk of birth trauma, instrumental delivery and caesarean section (NICE, 2020). It also increases the risk of developing type 2 diabetes in later life, with the reported lifetime risk being up to 60% (Noctor and Dunne, 2015). Furthermore, a history of GDM is associated with adverse

cardiovascular outcomes in its own right, with conventional risk factors such as type 2 diabetes, hypertension and dyslipidaemia only partially explaining this association (Lee et al, 2022).

NICE (2020) advises to inform women diagnosed with GDM about the risk of recurrence in future pregnancy. Lifestyle advice should be given (including, where available and eligible, referral to the NHS Diabetes Prevention Programme), and an HbA_{1c} screening test for diabetes should be performed at 6–13 weeks postnatally, and then annually thereafter. This monitoring is important as it may allow prevention of and early intervention for type 2 diabetes and CVD. It also allows for more intensive monitoring during a future pregnancy to minimise the risk of adverse maternal and neonatal morbidity. Although lipid and BP screening are not currently part of NICE guidance for the postpartum annual follow-up of GDM, Daprè (2024) argues that they should be considered. For more information, see [How to follow up gestational diabetes](#).

Citation: Kochhar S (2026) A quality improvement initiative to improve the care of women diagnosed with gestational diabetes. *Diabetes & Primary Care* 28: [Early view publication]

Article points

1. Monitoring is important for women with a history of gestational diabetes (GDM), as it may allow prevention of and early intervention in type 2 diabetes, as well as more intensive monitoring during a future pregnancy to minimise the risk of adverse maternal and neonatal morbidity.
2. This cohort is at increased risk of cardiovascular disease (CVD); therefore, modifiable CVD risk factors should be assessed as part of a holistic assessment. GDM may be considered a CVD risk factor.
3. Person-centredness is key in terms of engagement in proactive, preventative healthcare.
4. It is suggested that more than a third of people who participate in the National Diabetes Prevention Programme experience a risk reduction in the development of type 2 diabetes.

Author

Suneeta Kochhar, GP and Clinical Lead for Cardiovascular Disease Prevention and Women's Health, NHS Sussex.



**Read more
online**

How to follow up gestational diabetes

The crucial steps to screen for and prevent future diabetes, and cardiovascular disease, in women who develop gestational diabetes.

Diabetes & Primary Care
26: 165–7

[Click here to access](#)

Despite NICE (2020) recommendations and a Quality and Outcomes Framework indicator to encourage annual monitoring of non-diabetic hyperglycaemia, data suggests that in 2024–25, only 57% of women with a history of GDM received an annual HbA_{1c} measurement, whilst only 52% had BP checks, 45% BMI assessment and 35% cholesterol tests (NHS Digital, 2025). This means opportunities for early detection of modifiable CVD risk factors are being missed.

During pregnancy, a woman is likely to access healthcare more frequently and be more engaged in a proactive, preventative approach (Maas et al, 2021). This means that following a Making Every Contact Count (MECC) methodology towards lifestyle advice may improve both pregnancy outcomes and future CVD risk (Public Health England, 2020).

The present initiative

The aim of this quality improvement initiative was to offer monitoring of glycaemia and comprehensive assessment of modifiable CVD risk factors in women with a history of GDM, to support proactive, preventative care.

The project was carried out in a primary care-based Women's Health Hub in West Sussex and a Primary Care Network (PCN) in East Sussex. The Women's Health Hub delivers core services that include assessment and treatment of menstrual problems; menopause assessment and treatment; contraceptive counselling and provision of the full range of contraceptive methods, including long-acting reversible contraception; and cervical screening (Department of Health & Social Care, 2022).

Eligible participants were women with a history of GDM who did not have diabetes and who were not currently pregnant.

Procedure

Women were initially contacted by text messaging. If there was no response or a preference for another communication method was expressed, they received telephone calls or written communications. Telephone and face-to-face consultations were offered.

All women were counselled on the diagnosis of GDM and possible implications in relation to

future pregnancies and CVD risk, as clinically appropriate. Women were offered HbA_{1c} testing if they had not received this in the last year; further blood tests were requested at the same time if women were eligible for an NHS Health Check (Office for Health Improvement & Disparities, 2022). The cohort was offered BP checks and a BMI assessment. Further monitoring or treatment to target was offered to those with newly diagnosed or suboptimal management of hypertension. Detailed instructions were given on how to monitor BP at home and how and where to escalate concerns. Participants were advised on BP thresholds, and safety-netting advice was given about low or very high BP readings. Lipid-lowering therapy was offered according to NICE (2023) guidance.

All women were given advice on healthy living, including diet and exercise advice. Smoking cessation advice and referral to weight management services were offered if appropriate. All women were offered referral to the Healthier You: National Diabetes Prevention Programme (NHS England, 2023) if they were eligible. Women can self-refer or be referred by General Practice to Healthier You; the approach in the present initiative was refined after a pilot study to offer direct referral to improve uptake, based on feedback. Participants were signposted to additional resources, such as the Diabetes UK [Know Your Risk tool](#), as appropriate.

The project team took responsibility for results and was the point of contact for queries or concerns. Written communication was sent to the participants' registered GP following verbal advice, if required. During the project, participants were proactively followed up to ensure relevant actions such as treatment to target had taken place, and feedback was sought.

This pathway is summarised in *Figure 1*.

Results

Women's Health Hub data

The Women's Health Hub had a primary care-based population of 14 128 people, of whom 96 women had a previous diagnosis of GDM. All of these women participated in the proposed pathway. Ethnicity data and ages for the cohort are presented in *Figure 2*.




Figure 1. Proactive prevention pathway used in the quality improvement initiative.
BMI=body mass index; BP=blood pressure; CVD=cardiovascular disease.

At start of the project, HbA_{1c} had been recorded in 58 women (60.4%), BMI in 84 (87.5%) and BP in 76 (79.1%). At the end of the project, 100% of these women had all three of these metrics recorded.

No women in this cohort were eligible for lipid-lowering therapy, a reflection of younger age groups having a lower cardiovascular risk. One woman was diagnosed with hypertension and a further 14 had an existing diagnosis; all of these were confirmed as being treated to target by the end of the study.

Thirty-seven women were eligible for an NHS Health Check (38.5% of the cohort). Of these 21 accepted the health check (56.8% of those eligible). Ninety-four women were eligible for referral to the NHS Diabetes Prevention Programme (one was excluded due to pregnancy); of these, 37 accepted referrals to the programme (39.4% of those eligible).

It was noted that eight women were using weight loss injections (tirzepatide, semaglutide and liraglutide), accessed via the private sector.

PCN data

Within the PCN there was a combined GP practice population of 50 113, of whom 256 women were eligible for a GDM review. Of the latter, 15 women (5.8% of the eligible PCN population) did not participate; that is, they did not respond to multiple invitations, including via their preferred method of contact. Ethnicity data and ages for the cohort are presented in *Figure 3*. Response rates according to ethnicity and age group are presented in *Table 1*.

At the start of the project, HbA_{1c} was recorded in 124 women (51.5% of the cohort), BMI in 192 (79.7%) and BP in 147 (70.0%). At the end of the project, 100% of these women had all three of these metrics recorded.



Read more online

Hypertension case finding and treatment to target as part of the NHS diabetes eye screening programme

A pathway offering opportunistic blood pressure checks during eye screening to support hypertension case finding and follow-up.

Diabetes & Primary Care
26: 175–8

[Click here to access](#)




Figure 2. Ethnicities and ages in the Women's Health Hub cohort.




Figure 3. Ethnicities and ages in the Primary Care Network cohort.

No women in the PCN cohort were eligible for lipid-lowering therapy, again a reflection of younger age groups having a lower cardiovascular risk. There were no new diagnoses of hypertension, although 12 women had raised BP readings in clinic which were then normal on home BP monitoring. A further nine women had an existing diagnosis of hypertension, all of whom

were confirmed as being treated to target by the end of the study.

Ten women were eligible for an NHS Health Check (4.1% of the cohort), all of whom accepted. A total of 234 women were eligible for referral to the NHS Diabetes Prevention Programme (one was excluded due to pregnancy, two because they were already participating and

one because they had developed type 2 diabetes). Of these, 181 accepted referrals to the programme (77.4% of those eligible).

It was noted that 15 women were using weight loss injections accessed in the private sector.

Discussion

The outcome of the initiative was more effective monitoring of GDM. Through appreciative inquiry (Merriel et al, 2022), the outcomes developed further to assessment and management of modifiable CVD risk factors as well as referral for lifestyle advice.

The “vision” of having a proactive approach to women’s health was welcomed by participants and staff. Data analysis demonstrated strong patient engagement, together with high rates of referral to the NHS Diabetes Prevention Programme and BP measurement and management. Moreover, the team was mindful of weight bias and stigma surrounding lifestyle advice; therefore, person-centredness was key in terms of engagement in proactive preventative healthcare.

Feedback indicated that participants valued the opportunity to discuss proactive healthcare and appreciated scheduled follow-up to review results. Lack of time was cited as a barrier in accessing proactive healthcare, due to family and carer commitments. Therefore, some appointments were scheduled at weekends and in the evenings to support attendance.

It is estimated that over 80% of women do not understand GDM and nearly half feel stigmatised, reporting that healthcare professionals have made assumptions about diet and exercise (King’s College London, 2026). This stigma was corroborated in participant feedback in the pilot study to this project, particularly in relation to weight. It was recognised that this may in turn discourage women to take a proactive approach in relation to GDM monitoring; therefore, person-centredness that was respectful and compassionate was important (NHS England, 2025).

NICE (2020) advises that referral into the NHS Diabetes Prevention Programme should be offered to all women with a history of GDM. However, the first national GDM audit suggests that only 4.5% of eligible cohorts have participated in the programme (NHS Digital, 2025). The overall referral rate of 66%

Table 1. Non-response rate by ethnicity and age group in the PCN cohort.

Ethnicity	Number of participants	Non-responders
White	209	13 (6.2%)
Asian or Asian British	15	0
Black, Black British, African, Caribbean	4	1 (25.0%)
Mixed	5	0
Other	8	1 (12.5%)
Total	241	15 (6.2%)
Age group	Number of participants	Non-responders
<30 years	29	6 (20.6%)
30–39 years	104	4 (3.8%)
40–49 years	80	3 (3.8%)
50–59 years	22	2 (9.1%)
≥60 years	6	0
Total	241	15 (6.2%)

PCN=Primary Care Network.

in the present initiative compares favourably to this. Evidence suggests that more than a third of people who participate in the prevention programme experience a risk reduction in the development of type 2 diabetes (NHS England, 2023).

Information was made accessible with signposting to other resources. Text messaging, telephone calls and face-to-face consultations were facilitated to minimise the risk of digital exclusion and to support better communication, within an appropriate social and cultural context where relevant (NHS England, 2025).

The participant survey included details on age and ethnicity. It is known that GDM is disproportionately more common among women from ethnic-minority groups and those experiencing social deprivation (Hedderson et al, 2012). Therefore, completeness of the quality improvement study was evaluated to confirm that there was engagement from groups that may have increased health needs (NHS England, 2025).

The Quality and Outcomes Framework financial incentives may be highlighted to support



Read more online

Pre-conception advice for women with diabetes or previous gestational diabetes

A visual resource on the care elements required for pregnancy planning.

Journal of Diabetes Nursing
29: JDN363

[Click here to access](#)



**Read more
online**

**At a glance factsheet:
Diabetes before, during
and after pregnancy**

Essential information on reducing adverse outcomes in pregnancies complicated by diabetes.

Diabetes & Primary Care
23: 73–4

[Click here to access](#)

preventative care. Delivery was either through a Women's Health Hub or the PCN, using clinical pharmacists and administrative support. This required encouragement to develop collaborative relationships. The pathway was delivered in a primary care setting. Alternative community venues were considered but then discounted due to the need to perform phlebotomy and process samples. Outreach services may be developed but would require additional resources to make this a feasible option. Although translation and interpretation services were not required in this study, some women required additional face-to-face support due to low health literacy.

The study's success has now been replicated in a further Women's Health Hub in Sussex. The Women's Health Strategy references taking a life-course approach and listening to the voices of women, whilst being cognisant of disparities that should be addressed (Department of Health & Social Care, 2022). Moreover, it is consistent with the vision of the NHS 10-year health plan, which proposes a shift from treatment to prevention in the community, with use of digital technology to support communication and links to book appointments (Department of Health & Social Care, 2025).

Conclusions

This pathway aligns with the principles of shared decision-making and supported self-management. The Women's Health Strategy references taking a life-course approach whilst being cognisant of disparities that should be addressed. The pathway supported a preventative approach to modifiable CVD risk factors and development of type 2 diabetes. ■

Acknowledgements

The author thanks Agi Dixon and Laura Biddle at Victoria Road Surgery Women's Health Hub, Worthing; and Sascha Trani and Emma Cornford at Bexhill Primary Care Network, East Sussex.

- Daprè E (2024) How to follow up gestational diabetes. *Diabetes & Primary Care* **26:** 165–7
- Department of Health & Social Care (2022) *Policy paper: Women's Health Strategy for England*. Available at: <https://bit.ly/4h0rHFC>
- Department of Health & Social Care (2025) *10 Year Health Plan for England: Fit for the future*. Available at: <https://bit.ly/4hjNxVF>
- Hedderson M, Ehrlich S, Sridhar S et al (2012) Racial/ethnic disparities in the prevalence of gestational diabetes mellitus by BMI. *Diabetes Care* **35:** 1492–8
- Jeemon P, Uthup S, Anikkady N (2026) When risk is unequal: Gendered pathways to cardiovascular disease. *Glob Heart* **21:** 33
- King's College London (2026) *More than half of women with gestational diabetes subjected to "dangerous" stigma*. Available at: <https://bit.ly/3SXtflb>
- Lee SM, Shivakumar M, Park JW et al (2022) Long-term cardiovascular outcomes of gestational diabetes mellitus: A prospective UK Biobank study. *Cardiovasc Diabetol* **21:** 221
- Maas AHEM, Rosano G, Cifkova R et al (2021) Cardiovascular health after menopause transition, pregnancy disorders, and other gynaecologic conditions: A consensus document from European cardiologists, gynaecologists, and endocrinologists. *Eur Heart J* **42:** 967–84
- Merriel A, Wilson A, Decker E et al (2022) Systematic review and narrative synthesis of the impact of appreciative inquiry in healthcare. *BMJ Open Qual* **11:** e001911
- Mosca L, Benjamin EJ, Berra K et al (2011) Effectiveness-based guidelines for the prevention of cardiovascular disease in women – 2011 update: A guideline from the American Heart Association. *Circulation* **123:** 1243–62
- NHS Digital (2025) *National Gestational Diabetes Mellitus Audit*. Available at: <https://bit.ly/4A30ydlH>
- NHS England (2023) *NHS Diabetes Prevention Programme (NHS DPP)*. Available at: <https://bit.ly/4r6nuof>
- NHS England (2025) *Patient safety healthcare inequalities reduction framework*. Available at: <https://bit.ly/4ihU6ZW>
- NICE (2020) *Diabetes in pregnancy: management from preconception to the postnatal period* [NG3]. Available at: <https://www.nice.org.uk/guidance/ng3>
- NICE (2023) *Cardiovascular disease: risk assessment and reduction, including lipid modification* [NG238]. Available at: <https://www.nice.org.uk/guidance/ng238>
- Noctor E, Dunne FP (2015) Type 2 diabetes after gestational diabetes: The influence of changing diagnostic criteria. *World J Diabetes* **6:** 234–44
- Office for Health Improvement & Disparities (2022) *NHS Health Checks: Applying All Our Health*. Available at: <https://bit.ly/4yzAYvw>
- Peters SA, Huxley RR, Sattar N, Woodward M (2015) Sex differences in the excess risk of cardiovascular diseases associated with type 2 diabetes: Potential explanations and clinical implications. *Curr Cardiovasc Risk Rep* **9:** 36
- Public Health England (2020) *Making Every Contact Count: Evaluation guide for MECC programmes*. Available at: <https://bit.ly/4iVxiIS>
- World Heart Federation (2026) *Women & CVD*. Available at: <https://bit.ly/4gVdN7x>